How can Complex Innovative Design (CIDs) trials speed up the drug development pathway for immuno-oncology drugs?

View the accessible transcript of this podcast

Sarah Blagden talks to Professor Allan Gaw about why she co-led a paper outlining 10 consensus statements offering guidance to the clinical research community on the design and conduct of Complex Innovative Design (CID) trials.

She explains how these types of trials can speed up the drug development pathway and help to clear the backlog of of immuno-oncology drugs that are waiting to be tested, enabling cutting edge treatments can be offered to patients sooner. Sarah also describes why she thinks the UK is ideally positioned to conduct CID studies.

To find out more about how the NIHR supports complex and innovative design trials, visit the NIHR website: www.nihr.ac.uk/innovative-trials

This podcast is part of our pre-pandemic series of podcasts on Complex and Innovative Design (CID) trials. You can listen to all our full collection of #ComplexInnovativeDesign trial podcasts on our website.